Dutasteride significantly improves quality of life measures in patients with enlarged prostate

被引：16

作者：

O'Leary, M. P. ^{[1
]}

Roehrborn, C. G. ^{[2
]}

Black, L. ^{[3
]}

机构：

[1] Brigham & Womens Hosp, Boston, MA 02115 USA

[2] Univ Texas SW Med Ctr Dallas, Dept Urol, Dallas, TX 75390 USA

[3] GlaxoSmithKline Inc, Global Hlth Outcomes, Res Triangle Pk, NC USA

来源：

PROSTATE CANCER AND PROSTATIC DISEASES | 2008年 / 11卷 / 02期

关键词：

dutasteride; enlarged prostate; quality of life;

D O I：

10.1038/sj.pcan.4500990

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The purpose of this study was to determine the effect of dutasteride on quality of life of men with lower urinary tract symptoms associated with enlarged prostate or benign prostatic hyperplasia (BPH) as measured by symptom problem index (SPI), BPH-specific interference with activities (BSIA), BPH-specific psychological well-being (BPWB) and BPH-specific lifestyle adaptations (BSLA). Data were derived from three randomized, double-blind studies conducted in 4325 men treated with placebo or dutasteride (0.5 mg/day). Primary analyses included changes from baseline in mean SPI, BSIA, BPWB and BSLA scores. Men treated with dutasteride showed significant improvements in SPI, BSIA, BPWB and BSLA scores compared with placebo.

引用

收藏

页码：129 / 133

页数：5

相关论文

共 17 条

[1] Construct validation of the USA-Spanish version of the SF-36 health survey in a Cuban-American population with benign prostatic hyperplasia [J].

Arocho, R ;

McMillan, CA ;

Sutton-Wallace, P .

QUALITY OF LIFE RESEARCH, 1998, 7 (02) :121-126

[2]

BARRY MJ, 1995, MED CARE, V33, pAS145

[3] THE AMERICAN-UROLOGICAL-ASSOCIATION SYMPTOM INDEX FOR BENIGN PROSTATIC HYPERPLASIA [J].

BARRY, MJ ;

FOWLER, FJ ;

OLEARY, MP ;

BRUSKEWITZ, RC ;

HOLTGREWE, HL ;

MEBUST, WK ;

COCKETT, ATK ;

BLAIVAS, JG ;

WEIN, AJ .

JOURNAL OF UROLOGY, 1992, 148 (05) :1549-1557

[4] Pharmacological therapy of benign prostatic hyperplasia/lower urinary tract symptoms: an overview for the practising clinician [J].

Chapple, CR .

BJU INTERNATIONAL, 2004, 94 (05) :738-744

[5] Marked suppression of dihydrotestosterone in men with benign prostatic hyperplasia by dutasteride, a dual 5α-reductase inhibitor [J].

Clark, RV ;

Hermann, DJ ;

Cunningham, GR ;

Wilson, TH ;

Morrill, BB ;

Hobbs, S .

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2004, 89 (05) :2179-2184

[6] Benign prostatic hyperplasia: A progressive disease of aging men [J].

Emberton, M ;

Andriole, GL ;

de la Rosette, J ;

Djavan, B ;

Hoefner, K ;

Navarrete, RV ;

Nordling, J ;

Roehrborn, C ;

Schulman, C ;

Teillac, P ;

Tubaro, A ;

Nickel, JC .

UROLOGY, 2003, 61 (02) :267-273

[7] VALIDATION OF A NEW QUALITY-OF-LIFE QUESTIONNAIRE FOR BENIGN PROSTATIC HYPERPLASIA [J].

EPSTEIN, RS ;

DEVERKA, PA ;

CHUTE, CG ;

PANSER, L ;

OESTERLING, JE ;

LIEBER, MM ;

SCHWARTZ, S ;

PATRICK, D .

JOURNAL OF CLINICAL EPIDEMIOLOGY, 1992, 45 (12) :1431-1445

[8] Association of health-related quality of life and benign prostatic enlargement [J].

Girman, CJ ;

Jacobsen, SJ ;

Rhodes, T ;

Guess, HA ;

Roberts, RO ;

Lieber, MM .

EUROPEAN UROLOGY, 1999, 35 (04) :277-284

[9] NATURAL-HISTORY OF PROSTATISM - IMPACT OF URINARY SYMPTOMS ON QUALITY-OF-LIFE IN 2115 RANDOMLY SELECTED COMMUNITY MEN [J].

GIRMAN, CJ ;

PANSER, LA ;

EPSTEIN, RS ;

OESTERLING, JE ;

JACOBSEN, SJ ;

LIEBER, MM ;

GUESS, HA .

UROLOGY, 1994, 44 (06) :825-831

[10] The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia [J].

McConnell, JD ;

Bruskewitz, R ;

Walsh, P ;

Andriole, G ;

Lieber, M ;

Holtgrewe, HL ;

Albertsen, P ;

Roehrborn, CG ;

Nickel, JC ;

Wang, DZ ;

Taylor, AM ;

Waldstreicher, J .

NEW ENGLAND JOURNAL OF MEDICINE, 1998, 338 (09) :557-563